Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. - Wikidata - awgldk - TriplyDB

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

http://www.wikidata.org/entity/Q36836075

about

Nomograms in oncology: more than meets the eye Kallikreins as biomarkers for prostate cancer Notch signaling in prostate cancer: a moving target Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer Focal therapy in prostate cancer: the current situation Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical Prostatectomy Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer.Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.Adjuvant medical therapy for prostate cancer.Predicting 15-year prostate cancer specific mortality after radical prostatectomy.Gene expression pathways of high grade localized prostate cancer.Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.Prognostic models to predict overall and cause-specific survival for patients with middle ear cancer: a population-based analysis.Validation study of a web-based assessment of functional recovery after radical prostatectomy Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.Supervised regularized canonical correlation analysis: integrating histologic and proteomic measurements for predicting biochemical recurrence following prostate surgery Radiation therapy in prostate cancer: a risk-adapted strategy.Pre-treatment risk stratification of prostate cancer patients: A critical review.Current status of radical prostatectomy for high-risk prostate cancer.Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values.Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05)A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy Prediction of prostate cancer recurrence using quantitative phase imaging Oncologic outcomes of surgery in t3 prostate cancer: experience of a single tertiary center High-risk prostate cancer-classification and therapy.The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia.PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis.Tissue biomarkers for prostate cancer radiation therapy.Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database.Population-based study of long-term functional outcomes after prostate cancer treatment.

P2860

Q26830260-EF1E6407-C813-49C7-8475-EA7D6B2CDFB2 Q26862434-FDFD66E6-6C8C-4AD5-AE50-47BBC039A6F4 Q27001047-A914D6E0-CF21-417C-AC76-FB5DC03091EF Q27028084-F3AD6CDD-640A-45BD-97E8-211219F5B01F Q28242346-1233A43E-4DD5-4DCC-AA2A-3AA74466EABB Q28554583-75765940-14D4-48C7-B860-2272D174A514 Q28744173-EF7B16C9-3E2D-4B99-B32B-9D446B57BE4A Q31092851-ED11F47C-84D7-4F84-81E1-536E4CAD5D4B Q33631383-2086F2B0-7CE7-4342-9B6E-860C688B431E Q33719967-8B020688-ABF5-4B0F-969F-08A8E770E14C Q33745069-0C6BCC95-65E4-452E-838D-3656C5A6A4AD Q33758771-4709C1AD-1646-44A2-A02D-AFDF9780BC87 Q33759725-7643A929-F7C8-480E-B33E-5CE8413E7D58 Q33832517-E4BA4E56-3F52-4E9D-915C-F1527FB14200 Q33852664-CDE228AE-4C11-4A84-A17B-4276F38DA66E Q33898869-97BA7C9F-2940-47B3-B09C-632FEAA34609 Q33993472-426337FE-6C6B-4FBF-9D16-AF91579E3F27 Q34029623-D9CD49EA-F486-4447-B81F-3705B160DB44 Q34081632-304A19F7-8A88-4760-9EB7-4419E8BE18BE Q34086557-19A47D7A-EC11-44AC-A1E2-F30AA786F38E Q34105674-F40939E1-235F-42BA-B5A5-FA21BE46291B Q34111590-AC579524-3C2E-4B96-881F-135BDF7689A0 Q34268868-2EA4784C-DCA8-45F4-AD38-F4DB29F4D0FA Q34346841-89743C5B-D8B6-4599-938A-6D9593B5E38E Q34756267-D5602ADD-2ABA-4D25-A2A5-8C1837DC5A91 Q35022732-E44ED14F-2E9B-44B5-B4CB-BA78EB0F8921 Q35095184-3A2AB092-2E50-49BA-BAFE-0D8300FA5D5A Q35096149-AE912887-C1FA-4BD6-A28E-A262558D7067 Q35115736-8332B5C0-9A4C-41AA-BB24-E7B06125C990 Q35211723-76F5D584-830D-4E92-9E93-2C59F1818ECE Q35322697-7F977713-2D6F-4B55-B1C8-3FBA25888432 Q35608187-4DBF54A0-5306-4D7C-BCB6-C11BCE85C4CF Q35642310-A5E8EE4B-F360-4141-9A8A-840FDF89694E Q35869811-EF43D684-EA0E-4335-B684-14DFCC55A112 Q35894629-53067B08-6800-4D1F-A190-32CD8EE4F1D3 Q36033729-B886EB92-1808-48E0-A9E2-FDE0DDB12C6F Q36070403-D4E2243E-0A7D-4966-898A-DC7F011328EC Q36141341-6A7B18CB-81B2-43D2-9436-91E25A271F29 Q36199750-7C1DAD2A-6261-40A8-B36E-075588941C3B Q36260481-F83DEAB5-1FB1-4F7E-83A0-C5E60A13B6CD

P2860

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

http://www.wikidata.org/entity/Q36836075

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Prostate cancer-specific morta ...... prostate-specific antigen era.

@en

type

label

Prostate cancer-specific morta ...... prostate-specific antigen era.

@en

prefLabel

Prostate cancer-specific morta ...... prostate-specific antigen era.

@en

P1433

Q36836075-FDC2D655-28C3-488D-83AE-44046D5F0615

P1476

Q36836075-A1550993-CFF9-427E-84A8-9B25E78C2FEA

P2093

Q36836075-07814CCE-AACA-4C88-8DC9-6ABF7DB7ED35

Q36836075-361CA144-5802-45DD-A7A2-F1E2C66FD66A

Q36836075-3C87E8AC-E726-431B-BE60-B900CE8ADDF7

Q36836075-3DC48BB5-F565-4823-9030-4147158811F3

Q36836075-8EDFB377-A98A-48F6-AA26-CBA5C1F65B82

Q36836075-D2744A1E-FC26-4523-8024-9A63D4E2E455

Q36836075-F6E35F5F-9807-47E6-9D15-814BE6F9795F

Q36836075-FD1627D6-C137-4ACA-A402-026F4629ED7E

P2860

Q36836075-01C99DF8-A3E9-403C-9816-3D48BAB52970

Q36836075-064DAA07-5A5E-4DB2-BFFE-8EBBCD789BB1

Q36836075-0E9D9B14-BFEB-4CF8-B827-DE3389AA7F10

Q36836075-254B2393-8DAA-40CA-B876-A7927BF9E5E6

Q36836075-26FE80BA-F37A-4460-8A12-44D185CB6E6C

Q36836075-28D00274-4F57-46C9-98B2-FF414806A134

Q36836075-4EC8305E-6629-416C-82D9-A3EE54C36A5F

Q36836075-67AE7316-06CC-44D1-A272-7F402DA3FFC7

Q36836075-6A8EB189-14BE-4CBF-80FA-299D33427674

Q36836075-6B74FB5C-886A-40CC-8A6D-E117EC3FFD94

P304

Q36836075-D743D4D6-FA42-4914-8DE5-8EE72F45A55E

P31

Q36836075-6C84C1D7-D4D5-4FE6-8B28-60C4D77292C2

P356

Q36836075-DD94A481-4C01-4352-BA77-4948B869BD6D

P407

Q36836075-B40CB139-7029-40B9-942C-3FFFFAC3BB9A

P433

Q36836075-0D2870C5-4439-4ACA-966E-5F5C400FE9DF

P478

Q36836075-A4EFEC9E-4B6D-4D24-8586-FBC36642879E

P50

Q36836075-4D7D8FCE-9CF2-48A5-BBB8-05CF4B050B36

P577

Q36836075-FC411095-55CB-4353-8C22-EE10E33ADC68

P698

Q36836075-57125575-C0F6-48B5-8F35-6416345983F3

P921

Q36836075-11FD007E-D090-4C82-B6A1-482F4403A181

P932

Q36836075-BD930DF9-8C12-4621-9AC5-D0BDDF55A5D5

P356

JCO.2008.18.2501

P1433

Journal of Clinical Oncology

P1476

Prostate cancer-specific morta ...... prostate-specific antigen era.

@en

P2093

Andrew J Stephenson

http://www.w3.org/2001/XMLSchema#string

David P Wood

http://www.w3.org/2001/XMLSchema#string

Eric A Klein

http://www.w3.org/2001/XMLSchema#string

Fernando J Bianco

http://www.w3.org/2001/XMLSchema#string

James A Eastham

http://www.w3.org/2001/XMLSchema#string

Michael W Kattan

http://www.w3.org/2001/XMLSchema#string

Ofer Yossepowitch

http://www.w3.org/2001/XMLSchema#string

Peter T Scardino

http://www.w3.org/2001/XMLSchema#string

P2860

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults

Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.

Evaluating the yield of medical tests.

Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Radical prostatectomy versus watchful waiting in early prostate cancer.

Effect of screening and adjuvant therapy on mortality from breast cancer.

Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

20-year outcomes following conservative management of clinically localized prostate cancer.

P304

4300-4305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.2501

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J Vickers

P577

2009-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19636023

http://www.w3.org/2001/XMLSchema#string

P921

P932

3651598

http://www.w3.org/2001/XMLSchema#string